Year All2026202520242023 July 14, 2026 Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026 July 13, 2026 Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases July 10, 2026 Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling July 7, 2026 Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research June 2, 2026 Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics May 8, 2026 Alamar Biosciences Reports First Quarter 2026 Financial Results May 5, 2026 Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference April 30, 2026 Alamar Biosciences to Report First Quarter 2026 Financial Results on May 8, 2026 April 20, 2026 Alamar Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares April 16, 2026 Alamar Biosciences Announces Pricing of Upsized Initial Public Offering
July 13, 2026 Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
July 10, 2026 Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling
July 7, 2026 Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
June 2, 2026 Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics
April 20, 2026 Alamar Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
